Table 2.

Patient and disease charateritics at time of stereotactic ablative radiotherapy

Characteristic	Patient (n=66)	Lesion (n=134)
Pre-SABR PSA (ng/mL),	1.2 (0.01–95.8)
median (range) and mean	9.0
PSA (ng/mL), n (%)
0–5	45 (68.2)
>5–10	5 (7.6)
>10–20	7 (10.6)
>20	9 (13.6)
Total no. of metastases, no. of patients (%)
1	31 (47.0)
2	19 (28.8)
3	7 (10.6)
4	4 (6.1)
5	2 (3.0)
6	3 (4.5)
Regions treated, n (%)
Bone	41 (62.1)	89 (66.4)
Node	24 (36.4)	40 (29.9)
Other	3 (4.5)	5 (3.7)
Lesion gross tumor volume, cm3 (n=134)
Mean (Range)		9.09 (0.1–152.3)
Median		2.45

Abbreviations: SABR = stereotactic ablative radiotherapy; PSA = prostate specific antigen